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no association was found between stent forces and the occurrence of pain,
perforation, hemorrhage or fistula formation.
Conclusion: Both SAEs and recurrence of dysphagia following esophageal stent
placement were not associated with RF, AF or degree of elongation. It can be
speculated that their occurrence is a multifactorial process determined by a
combination of stent-, tumor- and patient-related characteristics.
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Introduction: The management of benign esophageal strictures is challenging.
Common causes are represented by peptic injury, caustic ingestion, radiation
treatment and anastomotic ischemia after esophageal resection. The first man-
agement strategy includes endoscopic dilation using bougies or balloons.
Although the immediate success rate is up to 90%, about 30% to 40% of
patients experience recurrent dysphagia within the first year of follow-up.
The management of such relapsing refractory cases consists of repeat dilations.
To provide alternative and more definitive treatment option, self-expandable
stents have been proposed. Three different types of stents have been used:
metallic (SEMS), plastic (SEPS) and biodegradable stents (BD).
Aims & Methods: We performed a systematic review and meta-analysis to
examine the efficacy of stent placement in the long-term resolution of dyspha-
gia in patients with refractory benign esophageal stricture (RBES). PubMed,
SCOPUS, Google Scholar were searched (up to January 2015). Studies recruit-
ing adults with RBES treated with stent placement were eligible. The success,
complication and migration rates were pooled by means of a random effect
model to obtain an odds with a 95% confidence interval (CI).Statistical hetero-
geneity was tested using the Q2 test (significance level: 0.05) and I2 statistic. If
high levels of heterogeneity among the trials occurred (I24= 50% or
P5 0.05), the sources of heterogeneity were explored by sensitivity analysis
and meta-regression analysis.
Results: Eighteen studies (444 patients) were eligible for inclusion. The pooled
clinical success rate was 40.5% (95%CI, 31.5%449.5%), yielding an odds of
0.68 (95%CI 0.46-0.98) with high heterogeneity (I2 = 65.0%). The meta-regres-
sion analysis showed stricture etiology as the only influencing factor. Patients
treated with plastic (SEPS) and metallic stents (SEMS) reported not signifi-
cantly higher success rates than patients treated with biodegradable (BD) stent
[SEPS4SEMS4BD: 46.2% (95%CI 27-66.3%)4 40.1% (95%CI 28.1-
54.1%)4 32.9% (95%CI 23.1-44.1%)]. The migration rate was 28.6%
(95%CI 21.9-37.1%) yielding an odds of 0.40 (95%CI 0.28-0.59), with SEPS
and SEMS reporting not significantly higher migration rates than BD stent
[SEPS4SEMS4BD: 33.3% (95%CI 19.4-51.5%)4 31.5% (95%CI 22.5-
42.2%)4 15.3% (95%CI 8.3-25.4%)]. The complication rate was 20.6%
(95%CI 15.3-28.1%) yielding an odds of 0.26 (95%CI 0.18-0.39) without sig-
nificant difference between stents [SEMS = BD4SEPS: 21.9% (95%CI 11.5-
37.5%) = 21.9% (95%CI 13.8-32.9%)4 19.4% (95%CI 12.3-30.1%)].
Conclusion: Stent placement for the treatment of RBES is effective in about
40% of cases. Since patients with RBES have only two possible treatment
options, i.e. life-long dilations or surgery, the overall success rate reported by
stent placement should not be considered negligible. Furthermore, the success
rates might be even higher in subgroups of patients, according to the stricture
etiology (i.e. post-surgery or post-radiotherapy strictures). Further studies
should investigate whether the clinical success rate varies according to the
stricture etiology.
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Introduction: POEM results in treatment success in more than 90% of operated
patients. Treatment success is usually defined as an Eckardt score (ES) 0-2 (or
0-3). The aim of our study was to assess whether there are any predictive factors
for only partial symptomatic improvement with residual symptoms (ES 1 or 2)
vs. complete symptomatic response (ES = 0).
Aims & Methods: Since 2012, we performed 87 POEM procedures in 86 patients
with achalasia. The overall treatment success at 12 months was 98%. We
analyzed clinical outcomes of 59 patients who have had a treatment success
(ES= 0, 1 or 2) and completed at least 6 months follow up (27 female, 32 male,
mean age 48 years). We performed multivariate logistic regression with stepwise
selection of predictors and tested equality of means for continuous variables for
the two target levels and Fisher’s exact test for independence of the target level
and factor variables.
Results: Among 59 analyzed patients, 36 (61%) had a complete symptomatic
response (post-POEM ES=0) while 23 patients (39%) had partial symptomatic
response (post-POEM ES 1 or 2). The mean age of patients with a complete
response was lower(51 vs. 42 years) as well as the frequency of pre-POEM
treatments (botulinum toxin injection or pneumatic dilatation; 11% vs.
35%). The patients with a complete symptomatic response had higher both
the pre-POEM IRP (mean 30.1 vs. 23 mmHg) and the mean basal LES tonus
(44 vs. 32 mmHg). The frequency of type II achalasia was higher in patients
with a complete symptomatic response (83% vs. 61%). Both groups did not
differ with regard to the procedure related data (length of the procedure, length
of myotomy, etc.). The stage of the disease (duration of symptoms, esophageal
width) and the frequency of partial recovery of esophageal peristalsis after
POEM (33% vs. 30%) were similar in both groups. Post-POEM esophagitis
was more frequent in patients with a complete symptomatic response (36% vs.
26%). In multivariate logistic regression analysis, only age (under 40, p=0.03),
pre-POEM basal LES-tonus (under 40 mmHg, p=0.04) and any prior treat-
ment for achalasia (p=0.04) have been found as independent predictors of
partial symptomatic response.
Conclusion: Among the patients with treatment success, approx. 40% do not
have a complete symptomatic response. Younger age, lower pre-POEM basal
LES tonus and previous treatment attempts with botulinum toxin or balloon
dilatation are independently associated, despite the overall treatment success,
with an incomplete symptomatic response.
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Introduction: Peroral endoscopic myotomy (POEM) has been described with
high success rates for the treatment of achalasia. However, persistence/recur-
rence of symptoms can occasionally occur after POEM.
Aims & Methods: Our purpose was to evaluate the feasibility, safety and effi-
cacy of salvage peroral endoscopic remyotomy (Re-POEM) for patients after
failed POEM. Fifteen patients with persistence/recurrence of symptoms
(Eckardt symptom score4) after previous POEM were identified from a pro-
spectively maintained database that included a total of 1454 consecutive acha-
lasia patients. The primary outcome was symptom relief during follow-up,
defined as an Eckardt score of3. Secondary outcomes were procedure-related
adverse events, lower esophageal sphincter (LES) pressure on manometry, and
reflux symptoms before and after Re-POEM.
Results: All patients underwent successful Re-POEM after a mean of 13.5
months (range 4–37 months) from the time of the primary POEM. The mean
operation time was 41.5 minutes (range 28–62 minutes). Submucosal tunnel
infection occurred in one case and was successfully managed with conservative
treatments. During a mean follow-up period of 11.3 months (range 3–18
months), treatment success was achieved in all patients. The mean symptom
score pre-treatment was 5.6 (range 4–8) compared with a mean post-treatment
score of 1.2 (range 0–3; P5 0.001). Mean LES pressure also decreased from a
mean of 25.0 mmHg to 9.5 mmHg after Re-POEM (P5 0.001). The overall
clinical reflux complication rate of Re-POEM was 33.3%.
Conclusion: Re-POEM seems to be a safe and effective salvage option for failed
POEM, resulting in short-term symptom relief in all patients and without
serious complications.
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Introduction: Actual problem of modern hepatology is to find new and atho-
genetic treatment of liver diseases. One of these methods could be cell therapy
with using hepatic stellate cells (HSC), that are thought to be regional stem cell
of the liver. Experiments on freshly isolated rat HSC transplantation confirmed
their participation in liver regeneration after partial hepatectomy (PH).
However, the role of freshly isolated and activated in vivo HSC transplantation
to rats undergoing PH and the injection of 2-acetylaminofluoren (AAF) is still
unknown.
Aims & Methods: To study the influence of transplanted HSC on activity of
liver regeneration after PH and AAF injection.
Before transplantation HSC were labeled by the gene of Enhanced Green
Fluorescent Protein (GFP). We selected the classical model of acute liver
damage – partial hepatectomy. In one case, we transplanted native HSC, in
the other – in vivo activated HSC. Activation was carried out by lead nitrate
injection into the tail vein of rats donor, HSC were isolated 2 days thereafter.
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To inhibit hepatocyte proliferation in the recipient rats, animals were adminis-
tered intraperitoneally AAF 5 days before and after surgery. The animals were
sacrificed after 1, 2, 3, 5, 7 and 14 days after the transplantation of HSC. Paraffin
slices were stained by immunohistochemistry with antibodies to desmin – marker
of HSC and e`-SMA - myofibroblast marker.
Results: GFPþ hepatocytes were detected (found, stained) in liver parenchyma
even at the first days after transplantation. All groups showed an increase in the
number of desmin - positive cells in the parenchyma. After transplantation of
freshly isolated and activated HSC to rats after PH and AAF administration, the
maximum number of such cells was found 2 days after surgery, then their number
gradually decreased. Desmin-positive HSC in animals after PH without AAF
injection retained in the liver longer: in case of freshly isolated HSC transplanta-
tion – till the 5th day, after in vivo activated HSC transplantation - till the 7th
day. In all the groups e`-SMA positive myofibroblasts were not detected.
Conclusion: Transplantation of native and activated HSC stimulates liver regen-
eration and contributes to hepatocytes repopulation without the risk of liver
fibrosis.
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Introduction: O-GlcNAc transferase (OGT), a unique glycosyltransferase, is
involved in metabolic reprogramming. Using transcriptome sequencing, OGT
was identified to be highly expressed in non-alcoholic steatohepatitis (NASH)-
associated hepatocellular carcinoma (NASH-HCC) compared to their adjacent
non-tumor tissues of 18 patients. However, the role of OGT in NASH-HCC is
still unclear.
Aims & Methods: We aim to investigate the functional role of OGT in NASH-
HCC and its potential clinical implication. The biological function of OGT was
determined by proliferation, clonogenicity, migration and invasion experiments
through gain- or loss- of OGT functional assays in vitro and in nude mice. OGT
target factors and pathways were identified by promoter luciferase assay, DNA
binding activity assay and Western blot. The effects of OGT on oxidative stress,
reactive oxygen species (ROS), lipid peroxide and endoplasmic reticulum (ER)
stress and ER stress-related cascades were also investigated. The clinical impact
of OGT was evaluated in 209 serum samples of 137 NAFLD patients and 72
control subjects by ELISA.
Results: OGT was upregulated in 12 out of 18 (66.7%) NASH-HCC tumor
tissues compared with their adjacent non-tumor tissues by transcriptome sequen-
cing. Enhanced OGT expression was further confirmed in an independent set of 9
pairs of human NASH-HCC tissues (66.7%) by Western blot and in six HCC cell
lines and two NASH-HCC cell lines, but silenced in normal livers and weak in
immortalized normal hepatocyte cell lines MIHA and LO2. OGT production was
significantly induced in MIHA cells treated with insulin (P50.01) or cholesterol
(P50.01). Ectopic expression of OGT in MIHA and LO2 cells promoted cell
growth, clonogenicity, migration and invasion ability; whereas stable knockdown
of endogenous OGT in two NASH-HCC cell lines had opposite effects.
Moreover, subcutaneous tumor xenografts of LO2 cells with stable OGT expres-
sion in nude mice exhibited an increased tumor growth compared with the con-
trol cells (P50.01). Mechanistically, OGT induced ROS production, increased
lipid peroxide levels and enhanced the protein expression of ER stress markers
GRP78 and IRE1 in LO2 and MIHA cells. In this connection, OGT signifi-
cantly activated JNK cascade as evidenced by increased protein expression of p-
JNK, p-c-Jun and activation of AP-1; induced NF-B pathway through enhan-
cing the protein levels of p-IKK/ p-IKK, p-p65, p-p50 and the NF-B DNA
binding activity in OGT-transfected LO2 cells compared to the control cells.
Moreover, the serum levels of OGT were significantly higher in patients with
steatosis (3.30 ng/ml vs 1.83 ng/ml, P50.0001) or NASH (3.49 ng/ml vs 1.83 ng/
ml, P50.001) compared with control subjects. The AUROC of diagnosing
NAFLD was 0.741 (95% CI: 0.671-0.812) and diagnosing NASH was 0.749
(95% CI: 0.681-0.816). Multivariate analysis showed that OGT was an indepen-
dent risk factor for NASH patients.
Conclusion: OGT plays an oncogenic role in NASH-associated HCC through
inducing ER stress and ROS production and consequently activating oncogenic
JNK and NF-B pathways. Serum detection of OGT may serve as a potential
diagnostic marker for NASH patient.
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Introduction: Angiogenesis is pivotal for the devolvement of portal hypertension
in cirrhosis. Somatostatin (SST) and its analogue octreotide are widely used for
the management of gastroesophageal varices bleeding. However, the molecular
and cellular mechanism of SST and octreotide on portal hypertension remains
unclear.
Aims & Methods
Aims: To investigate the mechanism of octreotide on regulation of portal
hypertension.
Methods: Peritoneal injection of thiacetamide (TAA) was employed to induce
liver cirrhosis (200 mg/kg every 3 days for 16 weeks). 36 male Sprague-Dawley
rats were randomized into control, TAA and TAAþoctreotide with 12 animals
in each group. TAAþoctreotide group received TAA plus octreotide (50 mg/kg/
day) from the initiation of TAA administration. TAA group received TAA plus
placebo and control group received injections of normal saline. Scanning electron
microscope of vascular casting, hematoxylin-eosin staining (HE), Masson tri-
chrome staining (MT) were applied to evaluation of cirrhosis and angiogenesis.
Portal pressure was also measured. Immunohistochemistry (IHC), quantitative
real-time PCR (qRT-PCR) and Western blot for alpha-smooth muscle actin (a-
SMA), collagen III, CD31, vascular endothelial growth factor (VEGF), phos-
phorylated extracellular signal-regulated kinase (p-ERK) and somatostatin
receptors (SSTRs) were determined. In vitro, human umbilical vein endothelial
cell line (HUVEC) was treatment with vehicle, octreotide, octreotide plus SSTR-
2 antagonist (CYN154806) or octreotide plus SSTR-5 antagonist (BIM23056) for
24 hours. Afterwards, wound-healing assay for cell migration, tube formation
assay for angiogenesis, immunocytofluorescence and Western blot for VEGF
and p-ERK were carried out.
Results: In vivo, compared with TAA group, liver fibrosis and portal pressure in
TAAþoctreotide group were remarkably decreased by 40.4% and 17.1%,
respectively. And the mRNA levels of a-SMA and collagen III in
TAAþoctreotide group were also reduced. Histological sections, vascular
casts of hepatic portal vein, IHC and qRT-PCR for CD31 showed that angio-
genesis in TAAþoctreotide group were dramatically reduced when compared
with TAA group. The up-regulation of VEGF, p-ERK and SSTR-2, SSTR-5
induced by TAA administration were significantly inhibited after treatment with
octreotide. In vitro, compared with vehicle treated cells, the migration rate, tube
length, VEGF and p-ERK protein were obviously substantially decreased in
octreotide treated cells. However, these inhibitory effects afford by octreotide
were remarkably restored by SSTR-2 antagonist but not SSTR-5 antagonist.
Conclusion: Octreotide could ameliorate portal hypertension in cirrhotic rat
through inhibition of intrahepatic angiogenesis. The anti-angiogenesis effect
afford by octreotide may attribute to regulation of integrated signal pathways
involving SSTR-2 - p-ERK – VEGF.
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Introduction: Epidemiological studies have shown that obesity and its related
non-alcoholic fatty liver disease (NAFLD) promotes the development of hepa-
tocellular carcinoma (HCC). However, the underlying genetic mechanism of
obese-related HCC is still largely unknown.
Aims & Methods: We aimed to uncover the genetic alterations of obesity-asso-
ciated HCC using cross-species oncogenomics and whole-exome sequencing.
HCC development in genetic obese (db/db) mice and dietary obese mice kept
on high-fat diet was monitored in comparison with wild-type lean mice kept
on normal diet treated with diethylnitrosamine (DEN). Paired HCC tumor
and adjacent normal samples from obese mice and lean mice were subjected to
whole-exome sequencing and cross-species oncogenomics to reveal genetic altera-
tion landscapes. Candidate mutation genes were further validated in HCC tumor
and adjacent normal samples from 16 genetic and 13 dietary obese mice and 16
control lean mice by PCR Sanger sequencing. The bio-functional significance and
molecular pathways of the candidate mutation genes was evaluated.
Results: Significantly higher tumor incidence, multiplicity and larger tumor size
of NAFLD-HCCs were found in both genetic and dietary obese mice compared
with those of lean HCCs in wild-type mice. Totally 277 and 268 genes were found
to be mutated in liver tumors from obese mice and control lean mice, respec-
tively, with only 8 genes overlapped by whole-exome sequencing. Eight impor-
tant metabolic or cancer-related pathways were significantly enriched in mutated
genes found in obese HCC, whereas only two pathways were enriched in mutated
genes found in lean HCC. Mutation frequency of Cel was significantly higher in
obese HCC than in lean HCC (34.5% vs. 6.3%, P5 0.05). Mutations in hRas
were detected in 10.3% of obese HCCs, all located at codon 61, but not in lean
HCCs. CEL inactivating mutation and hras activating mutation promote liver
cell growth. Inactivating mutation in CEL (D454E and D555N) led to the accu-
mulation of cholesteryl ester, which activated ER stress and consequent IRE1/
JNK/c-Jun/AP-1 signalling cascade; whist activating mutations in hRas (Q61R
and Q61K) activated MAPK and PI3K/PDK1/Akt signaling cascades to pro-
mote cell growth.
Conclusion: The genetic alterations of NAFLD-associated HCC are distinguished
from that of lean HCC. Mutations in CEL and hRas play important roles in
NAFLD-associated hepatocellular carcinogenesis.
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